TDNA ETF Price & Analysis

TDNA ETF Chart & Stats

$24.60

Market closed

$24.60

ETF Overview

T. Rowe Price Biotech ETF

T. Rowe Price Biotech ETF (TDNA) is an actively managed, sector-focused fund investing primarily in global biotechnology companies. Within the Health Care category, it targets the biotechnology niche, seeking exposure to businesses developing innovative medicines, therapies, and related life-science technologies. T. Rowe Price’s investment team uses fundamental, bottom-up research to evaluate companies’ scientific potential, product pipelines, competitive advantages, and financial prospects, with the goal of achieving long-term capital appreciation.

T. Rowe Price Biotech ETF (TDNA) Fund Flow Chart

T. Rowe Price Biotech ETF (TDNA) 1 year Net Flows: $9M

TDNA ETF News

Buy/Sell: Wall Street’s top 10 stock calls this week

What has Wall Street been buzzing about this week? Here are the top 5 Buy calls and the...

19h ago

Argenx Advances Empasiprubart Into Phase 2 for Guillain-Barré: What Investors Should Watch

Argenx ($ARGX) announced an update on their ongoing clinical study. Argenx (ARGX) has launched a new Phase 2...

20h ago

ARGX

Nuvectis’ In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It’s Not Even Their Lead Asset

WSW, NY, September 25th, 2026, FinanceWire Three months ago, Nuvectis Pharma (NASDAQ:NVCT) was an oncology developer anchored by...

24h ago

AZN

NVS

Natera price target raised to $460 from $350 at RBC Capital

RBC Capital raised the firm’s price target on Natera (NTRA) to $460 from $350 and keeps an Outperform...

24h ago

NTRA

Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on...

1d ago

CRL

NTRA

Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Scholar Rock Holding (SRRK) and Vertex Pharmaceuticals (VRTX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on...

1d ago

AXSM

SRRK

Goldman Sachs Remains a Buy on arGEN X (0QW0)

In a report released today, Rajan Sharma from Goldman Sachs maintained a Buy rating on arGEN X, with...

1d ago

ARGX

Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND), Natera (NTRA) and Aveanna Healthcare Holdings (AVAH)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on...

1d ago

AVAH

LGND

United Therapeutics Downgraded to Sell as Premium Valuation Clashes with Shrinking Core Business and Challenging Launch Outlook for Tyvaso and Jenraldi

United Therapeutics (UTHR) has received a new Sell rating, initiated by Goldman Sachs analyst, Andrea Newkirk. Andrea Newkirk...

1d ago

UTHR

Goldman Sparks Surge In Revolution Medicines Shares

Revolution Medicines ( ($RVMD) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual...

2d ago

RVMD

Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on...

2d ago

AGEN

DNTH

CoreWeave upgraded, Etsy downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

2d ago

Grail panel votes ‘closer than we expected,’ says BTIG

BTIG analyst Mark Massaro says following the FDA’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory...

2d ago

ABT

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Oruka Therapeutics (ORKA) and Harmony Biosciences Holdings (HRMY)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on...

2d ago

HRMY

ORKA

See More TDNA News

TDNA ETF FAQ

What was TDNA’s price range in the past 12 months?

TDNA lowest ETF price was $24.50 and its highest was $25.68 in the past 12 months.

What is the AUM of TDNA?

As of Sep 24, 2026 The AUM of TDNA is 9.82M.

Is TDNA overvalued?

According to Wall Street analysts TDNA’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does TDNA pay dividends?

TDNA does not currently pay dividends.

How many shares outstanding does TDNA have?

Currently, no data Available

Which hedge fund is a major shareholder of TDNA?

Currently, no hedge funds are holding shares in TDNA

TDNA ETF Smart Score

Outperform

Analyst Consensus

Strong Buy

Average Price Target:
37.51 (― Downside)

Blogger Sentiment

Neutral

Technicals

Learn more about TipRanks Smart Score

For ETFs, the calculations for the Smart Score, Analyst Consensus, Price Target, Blogger Sentiment, News Sentiment and Insider Transactions are based on the weighted average of the ETF's holdings and some additional factors. Hedge Fund Trend, Crowd Wisdom and Technicals are based on the actual ETF ticker.

Go to Top Smart score ETFs >